Culture Conditions |
|
|
|
|
Low pH |
Transformed murine L fibroblasts C6 glioma cells |
Reversible at neutral pH |
[16][44, 68] |
High cell density |
Transformed murine L fibroblasts C6 glioma cells |
|
[16][41, 42, 44, 68] |
Cell subculture |
HeLa cells |
Time in culture |
[152] |
MCF-7 cells |
|
[153] |
Grown in culture |
Human peripheral blood monocytes |
|
[24] |
Serum deprivation |
Transformed murine L fibroblasts |
|
[16] |
Jurkat T lymphoblasts |
[72] |
Serum |
Mixed peripheral blood cells |
|
[24] |
Human neutrophils |
[21, 78] |
Unsaturated fatty acids |
Neutrophils |
|
[21] |
AgX63.653 murine spleen myeloma cells |
[154] |
Autologous monocyte co-culture |
Human peripheral blood lymphocytes |
|
[24, 81] |
Growth as spheroids |
GaMG human glioma cell line |
|
[155] |
Senescence, extended passaging |
Human fibroblasts |
|
[82] |
|
Anticancer drugs and inhibitors |
|
|
|
|
Antimetabolites |
|
|
|
5-fluorouracil |
Transformed HBL-100 breast cells |
Chlorpromazine |
[70, 87] |
Microtubule stabilizers |
|
|
|
Paclitaxel |
Human erythroleukemia K562 cells |
|
[73] |
Liposome encapsulated |
BT-20, MCF-7 breast cancer cells |
|
[76] |
Microtubule depolymerizers |
|
|
|
Colcemid |
Jurkat T lymphoblasts |
|
[72] |
Topisomerase II inhibitors |
|
|
|
Etoposide |
HeLa cervical carcinoma cells |
|
[74] |
|
Murine EL-4 lymphoma cells |
|
[95] |
Antitumor antibiotics |
|
|
|
Daunorubicin |
Jurkat T lymphoblasts |
|
[40, 72] |
Doxorubicin |
Jurkat T lymphoblasts |
|
[40, 71, 72] |
|
Daudi B-lymphoma |
|
[72] |
|
JY lymphoblastic leukemia |
|
[72] |
|
HL60 leukemia cells |
Bcl-2 transfection |
[71, 72, 75] |
Glucocorticoids |
Jurkat T lymphoblasts |
|
[40, 72] |
Dexamethasone |
|
|
|
Fas monoclonal antibodies |
Jurkat T lymphoblasts |
|
[48] |
|
Hut 78, human lymphoblast cell line |
Triacsin C |
[85] |
Differentiating agents |
|
|
|
Phenylacetate |
DU145 prostate cells |
|
[46] |
Phenylbutyrate |
|
PPAR-γ antagonists |
[45, 46, 77] |
|
|
AACOCF3 |
[88] |
Cationic lipophilic phosphonium salts |
DU4475 breast cancer cells |
|
[20, 70] |
|
Transformed HBL-100 breast cells |
Chlorpromazine |
[2, 47, 69, 70] |
Cyclosporin A |
Transformed HBL-100 breast cells |
Chlorpromazine |
[86] |
Cell cycle blockers |
|
|
[1] |
Desferrioxamine, ADR 529 |
2609 Glioma cells |
|
[152] |
Lonidamine |
HeLa cells |
|
|
PC-PLC inhibitors |
|
|
|
D-609 |
NIH-3T3 mouse embryo fibroblasts |
Ras-transformation |
[83, 84] |
Thiazolidinediones |
|
|
|
Troglitazone |
3T3 F442A cells |
|
[156] |
|
Mitogens and Cytokines |
|
|
|
|
Phorbol myristate acetate ± ionomycin |
Jurkat T lymphoblasts |
|
[40, 157] |
|
Murine splenic and thymic T cells |
|
[22, 23, 79, 80] |
|
Human peripheral blood lymphocytes |
|
[81] |
Concanavalin A |
Murine splenic T cells |
|
[22, 26, 78] |
Anti-CD3 antibodies |
Murine splenic and thymic T cells |
D-609 |
[80] |
|
Human peripheral blood lymphocytes |
|
[80, 81] |
Lipopolysaccharide |
Murine splenic B cells, Human neutrophils |
|
[21, 26, 158, 159] |
Interferon-γ |
Mouse peritoneal macrophages |
|
[24, 25] |
|
Other |
|
|
|
|
Listeria monocytogenes |
Mouse peritoneal macrophages |
|
[24, 25] |
Ionizing radiation |
HL60 leukemia cells |
|
[75] |
|
MG-63 human osteosarcoma spheroids |
|
[160, 161] |
HIV-1 infection |
Lymphoblastoid cells |
Transient |
[162] |
Bacterial infection |
Human neutrophils |
|
[159] |
Caveolin-1 transfection |
K562 myelogenous leukemia cells |
|
[163] |
|
K562 myelogenous leukemia cells |
Taxol adriamycin resistance |
[164] |
|
MCF-7 breast cells, LoVo colon adenocarcinoma cells |
Multidrug resistance |
[165] |